Top 5 Astaxanthin Supplements of 2026 v2 – Clarity MD
The two chiefs
House chief · 7/10
comparison listicle advertorial on the seller's own store · pre-sell between the click and the product page · adults already shopping for astaxanthin, the sceptical end of that market · solution-aware · no named mechanism, three standards shown as chips
Lead: Method box first, then a shortened problem-solution lead (entries 6-8, 10-13). Grade B-: trust is built before interest, and the study count is traded for the reader's hopes.
Offer: Simple and strong: $29.99, a first-order discount, free shipping, ninety days to claim a refund. The price is stated three times and the guarantee five. No bundle detail, no bonus, no reason for the discount.
Close: The same three links (entries 34, 70, 72). The argument before them is a concession and a recap of method (entries 68-71); the loss line is cut. Safer, and weaker at the moment of decision.
Throughline: Flatter than the base page from the first screen: method, a softened mirror, then cards. What it gains is consistency: nothing on the page now contradicts anything else, except the presence of the last-placed product on a list of qualifiers.
Strongest
- The two-step rule: qualify on standards, rank on named factors (entry 18).
- Criteria chips as a system, from the first screen to the last card (entries 7, 20, 36, 43, 50, 57).
- A one-sentence reason for each rival's rank, above its lists (entries 36, 50, 57).
- Benefits carried as the reader's hopes inside the mirror (entry 11).
Weakest
- Separators that barely separate: three of the four rival cards credit outside testing and the runner-up matches the refund window (entry 69).
- A close with no stake (entry 71).
- No evidence of the test, now a larger claim: fifteen tried in person, none shown (entries 6, 9).
- A narrator with no credential who now shares the page with a plural publication voice (entries 4, 6).
Craft chief · REVISE
It reads like a careful consumer report with a person trapped inside it: the logic is mended, the voice comes and goes, and the close no longer lands.
Strongest
- Entry 18: the two-step rule that lets rivals pass every test and still rank lower.
- Entries 7 and 57: a code taught on the first screen and paid off when its values change on the last card.
- Entry 36: the reason for a rank in one sentence, above the lists.
Weakest
- Entry 69: three separators that most rival cards also claim.
- Entry 71: a close with no stake and no rhythm.
- Entry 43: a rank explained by a bottle's looks.
- Entries 41, 48 and 55: another publisher's small print, still in place.
001 PASS·noted: entry 11 keeps its pause; the policy sentences at entries 6 and 18 have no cadence, and the four fragments of the base close are gone · 002 PASS: attention (2-3), belief (6-18), desire (19-32), action (34, 70, 72); the links escalate from a look to a trial · 003 PASS·noted: plain in the intro; abstract nouns pile up at entries 6 and 18; a Latin species name at entry 16 · 004 PASS·noted: the contradiction in card four is removed (entry 52) and each rival card now opens on its reason; entries 53-54 still have no argument, and about sixty percent of the page passes between links (34 to 70) · 005 PASS·noted: the promise of criteria (2) is paid twice (entries 7, 14-17); the claim of testing in person is never shown, and entry 62 admits label reading · 006 PASS·noted: the chips make each pass concrete (entries 20, 57); the grades still have no method (19) and the discount at entry 25 has no reason-why · 007 PASS·noted: capitals at entry 16 stress a phrase the voice would not shout · 008 PASS·noted: the three criteria are stated seven times (first-screen chips, standards, the winner's chips, pros, verdict and bottom line, recap); each rival's reason is told three times within its card (entries 36, 38, 39) · 009 N/A: the lead is problem-solution in the first person, not a story · 010 PASS·noted: the first person drops out at entries 6 and 18, where a publication speaks in the plural; entries 11 and 46 still sound spoken · 011 PASS·noted: one picture row (9) with no alt text; the grades of cards four and five are not in live text (49, 56) · 012 REVISE: entries 41, 48 and 55 ship another publisher's small print; the first tab (5) names a section the page does not have · 013 PASS: entry 11 names the reader's frustration in the reader's own terms · 014 PASS·noted: the arc peaks at entry 12; the loss line of the base page is cut, so the close carries no feeling (entry 71) · 015 PASS·noted: one stock conversational opener (12); the mirrored contrast of the base page is gone · 016 PASS·noted: a Latin species name at entry 16 and a supplier's extract name at entries 44 and 52, none taught · 017 PASS·noted: curiosity and stakes are carried by headline and deck (2, 3); emotion has no carrier on the first screen · 018 PASS·noted: color lives in the chips as a system (7, 57), the two-step rule (18), the fallback line (40) and the dose arithmetic (60); the bodily image of the base hinge is lost · 019 N/A: not founder copy; the tester is a persona with no supplied voice · 020 REVISE: the same body runs under four titles on the store, with the five cards cloned word for word · 021 N/A: no email sequence in scope · 022 PASS: nothing sharp was marked down for being bold; claim worries are listed under leave, not in these verdicts · 023 PASS: the first screen names what the reader leaves with, the deciding factors and a ranking · 024 N/A: no product verb claims a decision that belongs to the buyer · 025 PASS·noted: fifty reviewed, fifteen tried and five ranked now agree between headline (2), method box (6) and recap (63); 'dozens' at entry 13 is a loose fourth figure, and a four-minute read is printed on about 2,000 words (4)
Take
- The two-step rule above the cards (entry 18): qualify on the standards, rank on named factors. It lets rivals pass every test and still place lower without contradiction.
- Criteria chips: taught on the first screen (entry 7), repeated on every card (entries 20, 36, 43, 50), and shown with failing values in the same code on the last (entry 57).
- One sentence under each rival's grade that states why it ranks where it does (entries 36, 50, 57).
- Benefits carried as the reader's hopes inside the mirror (entry 11), not as the writer's claims.
- Numbers reconciled into a funnel (reviewed, tried, ranked) and repeated unchanged in the recap (entries 6, 63).
- Each standard with its reason on the surface and the detail behind a link (entries 15-17).
- Winner first, about a fifth of the way down (entry 19); every later card is read against it.
- The winner's first three pros mirror the three criteria in the same order (entry 21); trust points next, then guarantee, crowd and price last (entries 22-25).
- Rival cards that send the reader back to rank one: the fallback line (entry 40) and the upward pointer (entry 47).
- The link ladder: two soft links (entries 34, 70) and one hard link with the guarantee in its wording (entry 72); no link inside any rival card.
Leave
- The funnel itself (entry 6): fifty reviewed and fifteen tried in person, with no list, date or photograph. Treat as invented. Our count is what we read.
- The policy register (entries 6, 18), which pushes the first person off the page.
- A rank explained by a bottle's looks (entries 43, 45).
- A chip that keeps a pass label over a failing figure (entry 57).
- Recap labels the wrong way round (entries 64, 65) and separators most rivals also have (entry 69).
- A close with no stake (entry 71).
- The tester's byline with no credential or trace (entry 4).
- Letter grades with no scoring sheet (entries 19, 35, 42), missing altogether on cards four and five (entries 49, 56).
- Another publisher's small print under the rival cards (entries 41, 48 and 55) and a publication named only in the footer (entry 73).
- Their delivery standard as a superiority claim (entry 17): banned for us (b8); the fat-soluble point (r26, r31) is what holds.
- Crowd and doctor claims with no source (entries 24, 29); our numbers wait for a measured panel (r17) and a named quote (r19).
- Their ninety-day window and first-order discount wording: our offer is BRAND section 3 and the 30-Day Money-Back Guarantee.
- Sold-out scarcity (entries 26, 40) unless a true stock statement exists.
Line by line · 73 entries
Every line is described in our words; the page's own text stays on the page (open it beside this table). Shaded rows carry the most pull.
| # | Beat | What the line does | Lever · reader | Why here | Craft | On our page |
|---|---|---|---|---|---|---|
| 1 0.2% | disclosure cta · 2 w | A two-word link at the very top marks the page as advertiser-funded. The terms sit behind the click; nothing on the page itself says who pays or who owns the winner. | candor solution-aware | It stands above the headline because that is where review publishers put theirs. A reader who meets it first files the page under comparison sites before any claim is made; placed after the pitch it would read as a confession. | Two words, no sentence. It works as costume more than as disclosure: the store that publishes the page also sells the product ranked first, and no line says so in plain words. | page-furniture CS-P1 has no disclosure link at the top; its 'Advertorial' byline tag was removed on 2026-09-15 and the supplement disclaimer sits in the footer. Whether a top-of-page disclosure returns is David's call. If it does, it names CellScience in plain words. |
| 2 0.7% | hook-headline h1 · 10 w | The first-person tester now claims fifteen well-known astaxanthin products tried, three times the base page's number, with the same promise to share which factors count. | curiosity-gapearned-authorityspecificity solution-aware | The click comes from someone who believes in the ingredient and is stuck on which bottle. The bigger number needs the method box that now follows the tabs; without it a list of five would contradict the headline. | One numeral changed. Fifteen is still believable and turns the top five into a selection, not the whole field. It sets up the funnel the method box spells out. | keep-structure CS-P1's H1 is a third-person list title that names four organs; it has no tester. Its count is five products read, five ranked. Do not raise our number unless we read more labels. |
| 3 1.8% | deck p · 19 w | The deck widens the credential to study reading plus trying several brands, promises a short list of deciding factors, and brands the products that miss them as costly duds. | loss-aversionopen-loopcontrast solution-aware | Directly under the headline it turns curiosity into a stake before the byline can be questioned. The reader already suspects brands differ; the deck confirms it, so the criteria section below is awaited, not endured. | One sentence of nineteen words, front-loaded with two credentials. The closing two-word insult is the only vivid phrase on the first screen. The count of brands goes vague here where the headline was exact. | rewrite-claim CS-P1's subhead counts softgels, tests and one winner and names the organs: it states structure, not the cost of a wrong pick. The true version of their jab is ours to use: about 64% of unverified astaxanthin products fail potency testing (c1). CS-P1 holds that figure in the method box, not on the first screen. c1 |
| 4 2.8% | authority-stamp 2× p · 12 w | A bare byline with a woman's name, then an updated date in July 2026 and a four-minute reading time. No title, no credential, no publication beside the name. | earned-authorityease solution-aware | It follows the deck because the 'I' of the headline needs a name before the argument starts. The date tells the shopper the ranking is current for the year in the page title. | Thin. A name with nothing behind it asks for trust in a stranger, and the reading time undersells a page of about 2,000 words. No bio, no link, no trace of her elsewhere: treat the tester as an invented persona. | keep-structure CS-P1 already carries a heavier stamp: a named health editor with sixteen years on the beat, a headshot, a date, a nine-minute read and a press strip. Our editor is a generated persona as well (BRAND log 2026-09-14), so the same question of disclosure applies to us. |
| 5 3.4% | page-furniture 3× p · 5 w | Three jump tabs sit under the byline: one for benefits, one for dosing, one for the ranked list. | ease solution-aware | Placed under the byline and above the new method box, where a news site keeps its section links. It previews the order of the page before the reader has scrolled. | One or two words per label. The first tab promises a benefits section the page never writes: benefits get a single sentence in the intro. | page-furniture CS-P1 has no jump tabs; its chassis uses a sidebar showcase and a sticky bar instead. Not needed unless scroll data shows readers hunting for the list. |
| 6 4.0% | ranking-criteria h3 · p · 40 w | A method box opens above the hero: more than fifty products reviewed, the fifteen best-known tried in person, five ranked by one method built on three research-backed factors. | earned-authorityspecificityobjection-preempt solution-aware | It is moved to the first screen, ahead of the picture and the problem. The base page made the reader wait for the yardstick; this one shows its method first, betting that a sceptical shopper grants trust to process before story. | Thirty-five words in two sentences, in the register of a consumer-testing outlet: abstract, with a long noun phrase for method. The heading speaks in the plural and the body in the singular. The funnel is asserted, with no list of the fifty or the fifteen; treat it as invented. | keep-structure CS-P1's method sits in a box after the intro, not on the first screen, and its counts agree (five read, five ranked). A short method line above the hero is a test; ours would state what we did: each rival's own page read on a stated date, three bars scored. c1 |
| 7 5.8% | ranking-criteria 3× p · 9 w | Three short chips name the factors: the dose with its number, the natural algae origin, and the oil-based format. | specificitycommitment solution-aware | They come directly under the method sentence, so the three factors are seen before they are argued. The same chips return on each product card; this is where the reader learns the code. | Two to four words each, noun phrases only. As a visual system they do what the base page's letter grades could not: show which tests a product passed. | keep-structure CS-P1 shows three score bars on every card but does not preview them at the top. Previewing our three bars under the subhead would teach the code early: the full 12 mg in one softgel (b7, b9), third-party lab tested (c1, c3), cost per day. b7b9c1c3 |
| 8 7.9% | ranking-criteria p · 11 w | One sentence promises that the reasoning for each factor follows further down. | open-loop solution-aware | It closes the method box and bridges to the body: the chips made a claim, this line defers the proof, and the picture comes next. | Eleven words of pure signpost in an official register. It could be cut without loss to a reader, but it signals thoroughness. | keep-structure CS-P1 needs no signpost: its method box carries each reason beside each criterion. |
| 9 8.7% | image img | A wide, shallow hero picture spans the column. It has no alt text, so the rows cannot say what it shows. | none solution-aware | The picture now follows the method box, so the first screen is headline, byline and method. The image has become a divider between the method and the problem, not the opening of the article. | It is still the only picture in the extract, and no product photograph in the cards was large enough to be captured. A page that now claims fifteen products tried in person shows none of them in hand. | keep-structure CS-P1's hero is our own bag with a caption calling it the top pick, so our winner is revealed on the first screen; this page keeps its hero neutral and holds the winner back until the list. A neutral hero (the five rivals side by side) is a test worth boarding. CS-P1 already shows a branded still in every rival card. |
| 10 10.0% | failed-solutions h3 · 8 w | The first subhead states that the majority of people who take the ingredient notice nothing, and implies the reason is coming. | curiosity-gapconsensusidentification solution-aware | With the method shown first, the argument proper starts here. The page tells the reader that a flat result is normal, ahead of the standards, because the standards are sold as the explanation for it. | Eight plain words, a question posed as a statement. It assumes the reader has bought the ingredient once already, which suits a comparison search and shuts out the newcomer. | rewrite-claim Most of our market has never met astaxanthin (p7), so the failed bottle on our page is the multivitamin and the vitamin C that never reach the inside of the cell (p3, r3, r5). CS-P1's intro already opens there; it has no subhead that names the disappointment. Never the collagen-stalled story (p1, p2). p7p3r3r5 |
| 11 10.5% | symptom-mirror p · 23 w | A second-person replay of the purchase that now lists what the reader hoped for (energy, skin, recovery, general wellbeing) before the flat result after some months. | mirroringidentificationhope solution-aware | The proof paragraph with its study count is gone, so this line now opens the intro. The benefits appear as the reader's hopes and not as the writer's claims, which removes the most exposed claim on the page while keeping the desire. | Twenty-three words in two sentences. The three-beat rhythm of the base page is traded for a list of four hopes; the pause before the letdown survives. Softer to the ear, safer on claims. | keep-structure Hopes stated as the reader's own, not as promises, is a clean way to name benefits: steadier energy (r7), eyes (b3), joints (b4), a clear head (r6). CS-P1 has no replay of a past purchase; its intro names organs as subjects of study. r7b3b4r6 |
| 12 11.3% | villain-reveal p · 20 w | The writer clears the ingredient and moves the blame onto the bulk of products, which supply it in a form the body cannot use. | vindicationcommon-enemyreason-why solution-aware | It answers the puzzle the previous line opened. Criteria can only be introduced now, because a test needs a fault to look for. The blame falls on a whole category, so every rival below starts under suspicion. | Tighter than the base version: twenty words, and the quantity hardens from plenty to the majority. The opener is a stock conversational frame. | rewrite-claim On our ranking page the honest villain is the unverified label: about 64% of unverified astaxanthin products fail potency testing (c1), and many brands sell 4 to 6 mg (b7). CS-P1 holds both points in its method box; its intro blames vitamins that pass through, not the category's bottles. c1b7 |
| 13 11.9% | turning-point p · 26 w | The writer says that across dozens of products and their research, three recurring patterns divided the effective from the ineffective. | earned-authorityopen-loopspecificity solution-aware | It is the hinge of the intro. The villain is named, so the reader wants the test for it, and the count of three matches the chips already seen on the first screen. It hands over to the standards. | Twenty-six words. The bodily image of the base page is gone, and with it the intro's best picture. The pool is now dozens, a loose figure beside fifteen and fifty. | keep-structure CS-P1 has this hinge in the editorial plural: five products bought, every label read, three things ranked. Ours rests on reading each rival's own page on a stated date, which is true. One mismatch to fix: CS-P1's subhead says three tests and its method box lists five things; this page holds the count at three until the scoring line. |
| 14 12.8% | ranking-criteria h2 · 7 w | The section heading now presents the three factors as scientific standards that underlie the ranking, not as requirements for every product. | borrowed-authorityspecificity solution-aware | Same slot as before, between problem and list. The softer frame matters for what follows: if these are entry standards, products that meet them can still be ranked on other things, which the scoring note goes on to admit. | Seven words. The verb of obligation is gone and an adjective of science arrives, with a plural possessive that belongs to a publication, not a lone tester. | keep-structure CS-P1 has a method box headed as five deciding things. Keep it, but let the heading count match the three score bars on every card (the full 12 mg in one softgel, third-party lab tested, cost per day). b7c1 |
| 15 13.5% | ranking-criteria h3 · h4 · p · 32 w | Criterion one is dose, now with a visible reason in two sentences: the daily amount that most trials used, and a hedged warning that a much smaller dose might not reproduce the findings. An expand link follows. | anchoringborrowed-authorityreason-why solution-aware | Dose goes first because it is the easiest thing to check on a label and the one test the last-placed rival will fail. The first criterion frames how the other two are read. | Twenty-five words, hedged twice. The register is that of a compliance review. The base page showed a title only; here the reason is on the surface and the detail behind a link. | keep-structure CS-P1's method box already gives the reason beside the criterion: the full 12 mg in one softgel, the dose the human trials used (b7, b9). b7b9 |
| 16 14.7% | ranking-criteria h3 · cta · p · 25 w | Criterion two is origin, now with a visible reason: the natural form from a named microalga is the one that most clinical work relied on. An expand link follows. | reason-whycontrast solution-aware | After quantity comes quality: once 12 mg is accepted, the next doubt is whether all 12 mg are equal. Source precedes delivery because delivery only matters if the raw material is right. | Nineteen words with the Latin species name, the only one on the page. The capitals of the title remain. The visible reason is about research practice; the promise of better uptake stays in the title alone. | keep-structure CS-P1's method box has this criterion and says openly that all five rivals pass it, so it did not decide the ranking: a candor move this page lacks. Rests on natural microalgae as the form the human studies used (c4), synthetic made from petrochemicals (r16), closed bioreactors (c5). c4r16c5 |
| 17 15.9% | ranking-criteria h3 · cta · p · 19 w | Criterion three is format, now with a visible reason: the ingredient dissolves in fat, so an oil base matters for uptake. An expand link follows. | contrastreason-why solution-aware | Last of the three because it is the least intuitive: the reader needed dose and source first to care how the dose travels. It closes the loop the intro opened about a form the body can use. | Thirteen words. The contest with dry powder stays in the title; the body makes the milder, chemical point. No product in the list is a dry powder, so the criterion still sorts nothing. | rewrite-claim The milder point is the one we can make: astaxanthin is fat-soluble (r26) and is taken with a meal that has some fat (r31). A carrier-oil superiority claim stays banned (b8). CS-P1 does not use a delivery axis; its second bar is third-party lab tested (c1, c3). r26r31c1c3 |
| 18 17.1% | ranking-criteria h2 · p · 41 w | Under the list title, a two-step method: every product listed first had to meet the three standards; the order was then set by editorial factors, named as outside testing, openness about ingredients, value and buyer protections. | reason-whycandorobjection-preempt solution-aware | It stands at the threshold of the cards, replacing the base page's single line of method. It answers in advance the question the base page raised at card two: if the formula is equal, why is the grade lower? | Thirty-five words of policy language. It repairs the logic and drains the voice: the first person disappears. One flaw survives: the last-placed product fails the dose standard, so not every product listed qualified. | keep-structure CS-P1 handles this inside its method box: the origin criterion is marked as passed by all five and so not decisive. The two-step statement is the general form of that candor and is worth a sentence above our first card. Our ranking factors are the three bars (b7, c1, c3); buyer protection for us is the 30-Day Money-Back Guarantee. b7c1c3c4 |
| 19 19.2% | ranked-entry h2 · h3 · 2× p · 9 w | Card one names the seller's own 12 mg product as rank one, gives the maker line and stamps it with the top letter grade. This is the product reveal. | anchoringearned-authority solution-aware | The winner comes first, about a fifth of the way down: a shopper who reads one card reads this one, and every later card is judged against it. The criteria just above make the grade feel derived. | Four rows, nine words. A letter grade is a shrewd unit: everyone has been graded at school, and a letter hides the absence of a scoring sheet. No sub-scores appear; the grade has no stated method. | keep-structure CS-P1 already ranks our product first, with a ribbon and three numeric score bars. Ours is the stronger form because the axes are visible. Name it as CS-P1 does: CellScience Astaxanthin 12mg, The Cell Shield. |
| 20 21.1% | ranked-entry 3× fine · 8 w | Three chips under the grade show the winner meeting each standard, with the dose figure inside the first chip. | loop-closedspecificity product-aware | They sit between the grade and the pros, so the letter is followed at once by its evidence. It is the code taught on the first screen, now applied. | Eight words in small type. They duplicate the first three pros directly beneath, so the winner's card states the criteria twice within ten rows. | keep-structure CS-P1's three score bars already do this, with a number on each axis. Keep ours. b7c1c3 |
| 21 22.2% | ranked-entry h2 · 3× p · 39 w | The first three plus points restate the three criteria in the same order (dose, source, delivery), each with a short reason after a colon. | loop-closedreason-whyspecificity product-aware | They lead the list while the criteria are still fresh; the matching order makes the grade look like arithmetic. Any other order would hide the fit. | Label, colon, reason: a mould a skimmer reads in two seconds a row. The first reason slips into the first person, which keeps the tester in the room. Row two holds the only named place of origin for an ingredient on the page. | keep-structure CS-P1's winner pros open with dose and testing, matching its first two score bars (b7, b9; c1, c3); the third bar, cost per day, has no pro. Origin follows (c4, c5). Whether a cost-per-day pro returns to the card is David's call (price line removed 2026-09-15). No oil claim (b8). b7b9c1c3c4c5 |
| 22 23.9% | ranked-entry 3× p · 37 w | Three trust points follow: outside-lab checks of purity and strength, a free-from label, and domestic manufacture in a certified facility. | borrowed-authorityobjection-preempt product-aware | With the formula accepted, the next question is whether the label can be believed. These come before the money points so that price is read as a bonus on a sound product. | Same mould. No lab is named, no report linked, no batch number given: testing is claimed in a phrase. The free-from row is three hyphenated adjectives in a line. | swap-proof Here our page is the stronger one: every batch third-party lab tested (c3, worded as 'lab tested' per the 2026-09-15 verdict) in a category where about 64% of unverified products fail (c1). Badges per r18: cGMP, Made in USA, gluten-free; vegan only if the shell is. CS-P1 has the testing line and no badge row in the card. c1c3r18 |
| 23 25.3% | guarantee p · 9 w | Plus point seven is the refund window: ninety days, with the promise put as a plain either-or. | risk-reversal product-aware | It follows the trust points and precedes crowd and price: a reader burned by one flat bottle needs the exit before the numbers. Inside a pros list a guarantee reads as something the tester found, not a sales promise. | Nine words. The second half is a slogan with rhythm: two short clauses joined by a conjunction. | swap-offer Ours is the 30-Day Money-Back Guarantee, keep the bag (BRAND section 3; the gate's 90-day wording in r22 is superseded by the lock of 2026-09-12). CS-P1's winner pros already end on it. |
| 24 25.7% | proof-social p · 12 w | Plus point eight joins an unnamed medical endorsement to a customer count above 142,000 and a rating of 4.8 on a five-point scale. | social-proofborrowed-authorityspecificity product-aware | Crowd proof lands after the guarantee and just before price: the reader has the facts and the exit and now learns they would not be alone. It is the only social proof until the verdict repeats it. | Label and reason do not match: the label promises doctors, the reason gives customers. No doctor is named and no review platform cited. Count and rating have no source; treat both as unverified. | swap-proof CS-P1 shows a customer count and rating in its sidebar and a comment thread that is still placeholder text (a launch blocker). Our cleared routes are the consumer-panel block once it has run (r17) and the longevity-doctor quote (r19). No number before it is measured. r17r19 |
| 25 26.1% | offer p · 15 w | The last plus point is price: $29.99 for today, a first-order discount of up to 70 percent and free domestic shipping. | anchoringurgency product-aware | Price closes the list: eight reasons first, the number last. Stated inside card one, it becomes the reference every rival price below is measured against. | Three offers in fifteen words. Two time words hint at a deadline without stating one. The discount ceiling and the single price do not add up on their face, and no reason for the discount is given. | swap-offer Ours: one bag $29.99, three bags $59.97, five bags $89.95, free shipping on every tier (BRAND section 3; the five-bag tier carries x4). CS-P1 took the price line out of the winner card on 2026-09-15 and states price in the CTA block. This page shows what an in-card price does to the rival cards below; David's call. x4 |
| 26 26.6% | ranked-entry h2 · 2× p · 20 w | The winner's two minus points: it is sold only through the maker's own site, and multi-packs run out during sales. | candorexclusivityscarcity most-aware | A pros list with no cons would break the review format. They follow the price, so the first thing the reader does with the price is worry about availability. | Two rows against nine. Neither is a fault in the product; both are reasons to act now. It is the oldest device in the format and a careful reader will see through it. | keep-structure CS-P1's 'worth knowing' block has the same two (official site only, r29; launch pricing on the multi-bag tiers) and adds a real limit: it is a daily supplement, not a treatment. Keep the real limit first; it is what makes the block believable. r29 |
| 27 28.1% | ranked-entry h3 · p · 23 w | Under a verdict label the tester says this was the only product that asked for no trade-off and that it has everything on her list. | earned-authoritycontrast most-aware | Lists persuade skimmers; a judgement in a voice persuades readers. It follows the cons so the last word on the product is the tester's and not the drawbacks'. | Two sentences, twenty-one words. The first carries a real idea (no trade-off). The second is filler that could sit on any product page. | keep-structure CS-P1 has this as a boxed paragraph explaining the top spot: the only product that passes all three tests at once. Same move, more specific. Keep ours. b7c1c3 |
| 28 29.3% | differentiation 2× p · 62 w | Two paragraphs replay the formula and the trust points as prose: dose, softgel and algae origin set against cheaper synthetic product, then testing, facility and label named as what settled it. | contrastcommon-enemyreason-why most-aware | The repetition is deliberate: the page is built so that a reader entering at any point meets the three criteria. The swipe at synthetics is safe here because none of the four rivals below is synthetic. | It sags. Both paragraphs are lists in sentence clothing, thirty-one words each. The one lively phrase is the jab about petrochemicals; a short idiom of decision keeps the voice alive. | swap-proof CS-P1's winner body does this in two paragraphs with our facts: natural microalgae (c4), closed bioreactors (c5), fat-soluble so less for the kidneys to handle (r26), and the organs named. The contrast with synthetic product is cleared (r16). c4c5r16r26 |
| 29 31.3% | proof-social p · 43 w | The verdict ends on numbers: the customer count, the rating and the doctors again, then the routine (one softgel daily, thirty in a pouch) and the ninety-day window. | social-proofeaserisk-reversal most-aware | The crowd comes last in the verdict, so the personal judgement is backed by numbers just before the bottom line restates the deal. | Forty-three words, the longest paragraph in the card, and it changes subject twice. Its opening clause admits the numbers are there as backup, which is honest about their job. | swap-proof Ours: one softgel a day with a meal (b9, r31), thirty to a bag, the 30-Day Money-Back Guarantee. Crowd numbers only once measured (r17). CS-P1 has the routine and the guarantee in the winner pros and no crowd line in the card. b9r31r17 |
| 30 32.2% | differentiation h3 · p · 25 w | A bottom-line label, then a contrast: many brands cut corners on each of the three criteria, and this one is pitched at buyers who refuse the shortcut. | common-enemycontrastidentification most-aware | A second summary label inside one card gives the scanner another entry point. It turns the criteria from tests into accusations just before the price is repeated. | Two sentences. The first is a tidy three-part list that maps one to one onto the criteria. The second ends on a cliché. | rewrite-claim We may say brands underdose at 4 to 6 mg (b7), that synthetic astaxanthin is made from petrochemicals (r16) and that most unverified products fail potency tests (c1). We may not make the capsule-against-oil point (b8). CS-P1 has no second summary inside the winner card. b7r16c1 |
| 31 33.3% | offer p · 34 w | One sentence stacks the three criteria and then the deal: today's price, the first-order discount and free shipping. | anchoringreason-why most-aware | Second statement of the price, now in a sentence that leads with value. It sits three rows above the link, so the deal is the freshest thing in mind at the click. | Thirty-four words in a single sentence that reads like a list with commas. A two-word pivot marks where it turns from product to price. | swap-offer CS-P1 keeps price out of the winner card (David's edit of 2026-09-15) and puts the per-bag price of the five-bag tier in the CTA block under it. Same slot, one step lower on the page. x4 |
| 32 34.2% | guarantee p · 40 w | The card's last paragraph notes the absence of fillers, restates the ninety-day refund and argues that the window is long enough for a fair trial. | risk-reversalreason-whyobjection-preempt most-aware | The guarantee is the last argument before the link because the doubt left, after one flat bottle, is whether this one will differ. Giving the ninety days a purpose answers how long until the reader will know. | Three sentences. The filler point is a stray that belongs with the label claims. The final sentence gives the guarantee a job, which most guarantee copy forgets. | swap-offer 30-Day Money-Back Guarantee, keep the bag. Our window is shorter, so its reason is what shows inside thirty days: steadier energy in weeks one to two (r7), eye strain relief in 14 to 28 days (b6). CS-P1 says this in its FAQ and timeline, not in the winner card. r7b6 |
| 33 35.3% | disclosure fine · 25 w | Small print under the winner's card says outcomes reflect individual users and are not typical, and refers the reader to the product's own site. | none most-aware | It sits between the last argument and the link in the smallest type on the page: present for a regulator, invisible to a reader moving toward the click. | Boilerplate of twenty-five words. It speaks of users' experiences although the card quotes no user. | page-furniture CS-P1 carries the supplement disclaimer once, in the footer. No per-card small print is needed. |
| 34 36.2% | cta p · 5 w | The first link out: a low-pressure invitation to read more about the winner, with an arrow. It asks for a look, not a purchase. | commitmentease most-aware | It stands at the end of card one, just over a third of the way down: the first point at which the whole case (criteria, grade, price, guarantee) has been made once. Any earlier and the review pose would break. | Five words and a plain verb. Keeping the word for buying out of the link keeps the page in character as a review. | keep-structure CS-P1 already places its primary CTA block directly after the winner card, with a harder button that carries the guarantee. A softer text link in the same slot is a test, not a gap. |
| 35 37.2% | ranked-entry 2× h2 · 2× p · 9 w | Card two names Rovina's 12 mg product at rank two with the next grade down, a single step below the top. | contrastcandor product-aware | It follows the winner's link: the reader who did not click now sees that the reviewer can praise a competitor. A near-equal second place is what makes first place believable. | The same four-row header as card one, so the eye compares like with like. The gap is one grade step. | keep-structure CS-P1 also has Rovina at rank two, marked down on its dose axis: four softgels a day to reach 12 mg, read on its own page on 2026-09-14. The two pages disagree on facts (this one says the count per bottle is not listed; we found sixty to a bag). Use only what we read ourselves. |
| 36 38.8% | ranked-entry 3× fine · p · 28 w | Three chips show the rival meeting every standard. A sentence then states why it ranks second: price and sales model, with the formula expressly cleared. | candorreason-whycontrast product-aware | It comes above the pros, so the reader knows the verdict before the detail. The base page left the reason for the verdict paragraph, a dozen rows lower. | Twenty-two words, plain. It names the winner inside the rival's card, in the first sentence the reader meets there. | keep-structure CS-P1 puts a tagline under each rival's name that does this job: what the rival gets right, then the catch. Already there, in a livelier voice. |
| 37 40.3% | ranked-entry h2 · 5× p · 32 w | Five plus points credit the rival with the full dose, algae origin, a coconut-oil base, a ninety-day refund and independent checks: it passes every criterion. | candorconsensus product-aware | Praise comes first: a rival that passes all three criteria proves the criteria were not rigged for one brand. It has to precede the cons so the markdown reads as fair. | Shorter rows than the winner's, five to seven words each, and nine rows shrink to five. The brevity is itself a ranking signal. | keep-structure CS-P1's rival cards each carry three pros, every one read from the rival's own page. Same move; ours is sourced. |
| 38 42.4% | ranked-entry h2 · 4× p · 27 w | Four minus points, none about the formula: a price near $39.99, best pricing tied to auto-ship, softgel count not shown, and online-only sales. | anchoringloss-aversioncontrast product-aware | The rival's price appears only after the winner's $29.99 has been stated twice, so ten dollars more needs no comment. Commercial cons keep the markdown defensible. | The mould again, six words a row. The online-only point is the same fact the winner's own cons carried as exclusivity: the page faults a rival for what it treats as a virtue in itself. | keep-structure CS-P1 marks Rovina down on routine (four softgels a day), supply (fifteen days to a bag) and test results available only on request, with price shown as a tier symbol. Ours is stronger because each con is a label fact. Do not borrow theirs. |
| 39 44.3% | ranked-entry h3 · 2× p · 104 w | The verdict praises the rival's fundamentals, places it just behind the winner on price and sales model, flags the missing softgel count and credits its refund window. | candorreason-whycontrast product-aware | The reason for the rank was already given in one sentence above the pros. The verdict now repeats it at length and names the winner again inside the rival's card. | A paragraph of sixty-six words, then one of thirty-six. Conversational and exact on price. With the new reason line above, this is the third telling of the same two faults in one card. | keep-structure CS-P1's rival bodies have the same shape: two paragraphs, praise first, then label facts. Already there. |
| 40 47.4% | ranked-entry h3 · p · 42 w | The rival's bottom line recommends it only as the fallback should the winner be out of stock, then repeats that it costs more but is an honest formula with a long refund window. | scarcitycandoranchoring product-aware | It closes the strongest rival's card, the point where a reader might defect. The fallback framing sends them back up the page, and no link to the rival is offered. | The opening conditional is the cleverest sentence in the rival cards: a recommendation that sells the other product. | rewrite-claim CS-P1's rival cards end on a price tier and a short verdict tag, not on a fallback line. The device transfers only with a true stock statement; we have launch pricing on the multi-bag tiers, not a stock limit. Without one, the pointer back to rank one is the part to keep. |
| 41 48.6% | disclosure fine · 22 w | Small print under the rival's card credits the results to a named ranking system that belongs to another review publisher: a leftover from the template this page was cloned from. | none product-aware | It sits at the foot of each rival card by template habit. Its content gives away the page's origin: the chassis of a third-party review site, reused by a seller. | A tell. The system it names appears nowhere else on the page, and the footer claims a different publisher. Treat the ranking system as nonexistent here. | drop Nothing to take. CS-P1's builder asserts that no donor string survives the purge; keep that assertion. |
| 42 49.8% | ranked-entry 2× h2 · h3 · p · 11 w | Card three names Double Wood's product at rank three, with a grade in the B band, one step below the runner-up. | contrast product-aware | By the third card the reader expects a drop. The step from the A band to the B band marks where nearly-as-good ends and good-for-the-money begins. | The same header mould. The grade ladder so far is evenly spaced, which makes it look computed. | keep-structure CS-P1's rank three is BioAstin; Double Wood is not in our list. Keep our own four rivals, each verified on its own page and each the same species of product (CL-13). |
| 43 51.4% | ranked-entry 3× fine · p · 24 w | Chips show all three standards met. The reason for third place is given as packaging and extras, with the formula cleared. | candorreason-why product-aware | Same slot as on card two, above the pros. The reader meets the reason before the price row that would otherwise make third place look wrong. | Eighteen words. Stated this baldly the reason exposes itself: a product is placed third for its bottle. Honest and weak at once. | drop The slot transfers; the reason does not. We rank on the three bars, never on a bottle's looks. CS-P1's taglines give label facts as the catch. |
| 44 52.9% | ranked-entry h2 · 4× p · 29 w | Four plus points: a full 12 mg of a branded extract, outside testing in a certified US facility, about $25.95 for sixty softgels, and a free-from formula. | candorspecificity product-aware | The lower price is admitted openly, two cards after the winner's price was set. The page has to deal with the bargain somewhere and does it mid-page, where fewer readers are. | The branded extract name appears unexplained; a stranger would not know it is an ingredient supplier. The price row is the most exact on the page: dollars, cents and count. | keep-structure CS-P1 concedes value openly in its Sports Research card (lowest cost per day on the list). Already there. |
| 45 54.9% | ranked-entry h2 · 5× p · 38 w | Five minus points, all cosmetic or circular: a plain bottle, no added vitamins, olive oil as the carrier, mostly direct sales, and no bonus ingredients. The second and fifth are one point stated twice. | contrastanchoring product-aware | The rival passed all three criteria and costs less for twice the count, so the markdown has to come from outside the criteria. The cons follow the price row at once, to blunt it. | The weakest list on the page. Packaging is not a criterion, and a single-ingredient formula is what the winner is too. A reader doing the arithmetic will see the winner costs more per softgel. | drop We do not invent cosmetic faults: CS-P1's rule is rival copy that is accurate and fair, every line read on the rival's page. Where a rival is cheaper, CS-P1 says so and wins on the lab-testing bar (c1, c3). c1c3 |
| 46 57.4% | ranked-entry h3 · 2× p · 87 w | The verdict admits surprise, credits the full dose at about $26 in an olive-oil base and the testing, and concedes only a plain bottle and no extra antioxidants. | candorspecificity product-aware | Mid-page, with the winner's case already made, generous praise costs little and buys trust for the final recommendation. | It opens on a three-word sentence with real voice, and the quip about looks is the only joke on the page. Thirty-two and fifty-three words: the praise outruns the criticism. | keep-structure CS-P1 does this in its value-pick card, which opens by granting that the rival would win on price alone. Already there. |
| 47 60.1% | ranked-entry h3 · p · 52 w | The bottom line calls the rival one of the best values listed and sends readers who care about extras or presentation back up the ranking. | candorcontrast product-aware | At the foot of the value card the page sorts readers by motive. The upward pointer is the only navigation cue inside the rival cards. | Four sentences, forty-nine words. The pointer is a quiet call to action with no link attached. | keep-structure CS-P1's cards end on a verdict tag with no pointer back to rank one. A one-line pointer at the foot of our value-pick card is worth adding. |
| 48 61.7% | disclosure fine · 22 w | The same leftover small print as under card two, crediting another publisher's ranking system. | none product-aware | Template position, the foot of every rival card. Repeated word for word, it becomes easier to notice with each card. | Identical to the line under card two. Repetition makes the borrowed chassis easier to spot. | drop Nothing to take; CS-P1 has no per-card small print. |
| 49 62.8% | ranked-entry h2 · h3 · p · 9 w | Card four names Sports Research's product at rank four. The grade label prints, but no letter reaches the text rows: the grade is an image or missing. | contrast product-aware | Fourth place is where attention is thinnest. The card is there to make five, and to hold a well-known retail brand below the winner. | From here the template frays: a label for the grade with nothing readable beside it. | keep-structure CS-P1 has Sports Research at rank four too, with three score bars in live text. Keep ours. |
| 50 64.5% | ranked-entry 3× fine · p · 35 w | Chips show all three standards met. Fourth place is explained by an unbranded, untraceable strain and a higher daily cost than bulk options. | candorreason-why product-aware | Same slot, above the pros. It prepares the shortened cons list, which now holds only what this sentence names plus one point on retail storage. | Twenty-nine words. The traceability point is the first reason in the rival cards that touches quality and not commerce. | keep-structure CS-P1's tagline for this rival names the same kind of gap in our terms: a tested badge and no batch report. Already there. c1c3 |
| 51 66.3% | ranked-entry h2 · 3× p · 20 w | Three plus points, each a pair of claims: full dose in a triple-strength softgel, a vegan shell with coconut oil, and non-GMO verification with outside testing. | candor product-aware | Praise opens the card as in the two before it; by now the reader takes the pattern for fairness. | The separator changes from a colon to a middle dot, and each row packs two claims with no reason given. A different hand, or a different source, filled in this card. | keep-structure CS-P1's card for this rival has three pros read from its own page. Already there. |
| 52 67.9% | ranked-entry h2 · 3× p · 38 w | Three minus points remain: an unbranded algae extract, a daily cost above that of bulk tubs, and storage that varies because many retailers carry it. The two rows that faulted the dose are gone. | contrastreason-why product-aware | With formula, price and testing conceded, only traceability and retail handling are left to fault. They appear in the fourth card, where scrutiny is lowest. | The edit removes the base page's contradiction with its own first criterion. What is left is consistent and thin: three rows, none about what the softgel contains. | drop Nothing here transfers. CS-P1 marks this rival down on one thing: a tested badge with no batch report to open, against our third-party lab testing (c1, c3). c1c3 |
| 53 70.0% | ranked-entry h3 · p · 39 w | A one-paragraph verdict describes the product neutrally: full dose from algae in coconut oil, a plant-based shell that is rare among the five, sixty softgels for two months. | candor product-aware | The verdict slot has to be filled for the card to match the others; nothing here moves the reader. | It reads like a product listing. The first person vanishes for thirty-seven words. | keep-structure CS-P1's body for this rival has a point of view in both paragraphs (the value, then the missing report). Keep ours. |
| 54 71.6% | ranked-entry h3 · p · 72 w | The bottom line calls the product easy to trust, repeats its strengths, reduces the complaints to two minor ones and ends by recommending it to the majority of buyers. | candor product-aware | It closes a card that had little to say against the product. Its praise is affordable this low on the page, where few undecided readers remain. | Sixty-nine words, the longest paragraph among the rival cards, and it undercuts the rank: a product judged sound for nearly everyone sits fourth with no grade. Praise and position do not match. | drop A rank has to follow from the scores. CS-P1's three bars make each position checkable; do not take praise that contradicts placement. |
| 55 73.6% | disclosure fine · 22 w | The same leftover small print a third time, crediting another publisher's ranking system. | none product-aware | Template position, the foot of every rival card. | Identical to the lines under cards two and three. | drop Nothing to take; CS-P1 has no per-card small print. |
| 56 74.8% | ranked-entry h2 · h3 · p · 9 w | Card five names Life Extension's product in last place. Again the grade label prints with no letter in the text rows. | contrast product-aware | Last place is kept for the best-known catalogue brand: the biggest name falls furthest, which flatters the unknown winner. | The same frayed header as card four. | keep-structure CS-P1's rank five is Dr. Mercola, marked down on cost per day and on no test report on its page. Life Extension is not in our list. |
| 57 76.4% | ranked-entry 3× fine · p · 31 w | The three chips carry failing values this time: a 4 mg dose, a marine source, a different delivery aid. A sentence names the gap: a third of the standard dose and a non-algae origin. | contrastspecificityreason-why product-aware | It is the payoff of the chip system: four cards of identical chips, then one where the values change. The reader who learned the code on the first screen can read the failure without the prose. | The first chip keeps the label for a clinical dose while holding a figure that fails it, so it reads as a pass unless the number is noticed. The sentence is twenty-five words and clear. | rewrite-claim The underdose contrast is cleared for us (b7: 12 mg against brands that sell 4 to 6 mg). CS-P1's five are all 12 mg products (CL-13), so its dose bar fails a rival on softgels per day. A failing score shown in the same bar is already how CS-P1 marks it. b7 |
| 58 77.9% | ranked-entry h2 · 3× p · 42 w | Three plus points: an established name with quality control, phospholipids added to aid absorption, and a low price of about $12 a month. | candoranchoring product-aware | The low price is conceded first so that the cons can undo it. The reader has to hold the $12 figure in mind for the dose arithmetic that follows to bite. | The third row mixes a price with a remark about broad marketing, two unrelated points in sixteen words. | keep-structure CS-P1 grants each rival its real strengths before the facts that mark it down. Already there. |
| 59 79.8% | ranked-entry h2 · 7× p · 116 w | Seven minus points, the page's longest list: 4 mg a softgel against the 12 mg standard, a triple daily count to match it, a proprietary blend, a small bottle, a marine source, and a cost that climbs at full dose. | contrastreason-whyspecificityloss-aversion product-aware | The only outright failure is kept for last place. It is the payoff of criterion one: a familiar, cheap brand fails on dose, which proves the yardstick was worth learning. | The first two rows and the sixth are strong and arithmetical. Then the list pads: the rows on bottle size and softgel type are filler, and the last repeats a phrase from the pros. Seven rows against the winner's two is proportion used as argument. | rewrite-claim The contrast is cleared for us: 12 mg clinical strength against brands that sell 4 to 6 mg (b7). CS-P1's list has no underdosed rival, since all five are 12 mg products (CL-13), and its dose bar separates on softgels per day. An underdosed fifth card needs a same-species rival whose label we read ourselves. b7 |
| 60 84.5% | ranked-entry h3 · p · 78 w | The verdict trusts the brand and likes its absorption aid, then turns on the label number: 4 mg equals one third of the research dose, so it takes three softgels daily to equal one from the top picks. | reason-whyspecificitycandor product-aware | The list stated the fault; the prose proves it with division. It comes at the bottom of the ranking so that the last thing learned from the rivals is that dose decides. | Seventy-six words, the longest and best-reasoned paragraph on the page. It closes on a three-part sentence that pays two compliments before naming the fault. | keep-structure CS-P1 does the same arithmetic in its Rovina card (four softgels a day, a bag lasts fifteen days), from that rival's own directions. Already there. b7 |
| 61 86.7% | ranked-entry h3 · p · 55 w | The bottom line says the product does no harm, repeats that 4 mg is an underdose, and argues that the low-priced bottle stops being a bargain once enough softgels are taken to reach 12 mg. | anchoringreason-whyloss-aversion product-aware | It is the last rival sentence before the winner returns. Ending the ranking on the idea that cheap is not cheap shields the winner's price from the cheaper bottles in the list. | Fifty-two words. The closing clause points away to an unnamed elsewhere instead of naming the winner, which keeps the reviewer's tone. | keep-structure CS-P1 scores cost per day on every card, so the per-day arithmetic is already a bar, not a remark. Keep ours. |
| 62 88.4% | disclosure fine · 19 w | The small print changes for the last card: results are said to rest on what the product's own label and advertising state. | none product-aware | Template position, the foot of the card. It is the last line of the ranking proper, directly above the winner's return. | The one disclaimer that tells the truth about the method: the rival was judged from its label. It contradicts the headline's claim of testing. | keep-structure This is the honest version of the method, and it is ours: CS-P1 says in its intro that every label was read. Say it once, in the method, not in small print. |
| 63 89.4% | close h2 · p · 23 w | The heading re-crowns the seller's product. The tester repeats the headline's fifteen and says a single brand offered the best package overall. | earned-authorityexclusivityspecificity most-aware | At the foot of the ranking the reader has just seen the weakest product. The page brings the winner back at once, before attention drops, and repeats the headline's number so the recap reads as the conclusion of the test. | The number now matches the headline. The claim drops from getting everything right to the best package, which concedes that others got the essentials right too. The sentence has no end stop. | keep-structure CS-P1 ends on a final CTA block about the product that passed all three tests, after the timeline, comments and FAQ; it has no re-crowning section directly under the last rival. Add one. The count in it matches the headline, as it does here. |
| 64 90.7% | differentiation 4× p · 27 w | A label for the reasons behind first place, then the three criteria ticks: dose, source and delivery, each with its bracketed reason. | loop-closedreason-why most-aware | Third pass through the same three points: standards, pros, recap. The new label splits the recap in two, so the reader is told which ticks are the reason and which are extras. | The three ticks are ones every rival but the last also earns, so the label promises a distinction the ticks do not deliver. | keep-structure Recap our three bars in their order: the full 12 mg in one softgel (b7, b9), third-party lab tested (c1, c3), cost per day. CS-P1 has a proof bar with three short items but no ticked recap beside the winner's name. b7b9c1c3 |
| 65 92.0% | differentiation 3× p · 17 w | A second label for extra advantages, then two ticks: outside testing the buyer can verify, and a free-from label with no fillers. | borrowed-authorityreason-why most-aware | They follow the three criteria in the order the pros list used. The label files them as additions, directly after the ticks that were labelled as the reason for first place. | By the page's own two-step method these extras are what decided the order, yet they are filed as additions. The two labels are the wrong way round. Nothing on the page links to a report, so the promise that the buyer can check is not kept. | swap-proof Ours can keep the promise: third-party lab tested every batch (c3), against about 64% of unverified products failing (c1). CS-P1 states it in the winner card and the proof bar. c1c3 |
| 66 93.1% | offer 2× p · 17 w | The last two ticks are the ninety-day refund, described as time enough to judge, and the price of $29.99 with the discount ceiling. | risk-reversalanchoring most-aware | Third statement of the price and fourth of the guarantee. They close the checklist so the final items read before the brand name are the two that lower the cost of saying yes. | Eight and nine words. The label claims best value, although two products in the ranking cost less per softgel. | swap-offer 30-Day Money-Back Guarantee, keep the bag; $29.99 for one bag, $59.97 for three, $89.95 for five, free shipping (BRAND section 3, x4 on the five-bag tier). CS-P1's CTA blocks carry this; a recap list would restate it. x4 |
| 67 93.7% | close p · 4 w | A sentence of four words gives the brand's name as the answer to the checklist. | loop-closed most-aware | It comes after the ticks, not before, so the name arrives as a conclusion. The reader has known it since card one; the delay is for rhythm. | Short, flat, final. The reveal is cadence, not news. | keep-structure If we add a recap, it ends on the full noun: The Cell Shield, from CellScience. CS-P1's final heading alludes to the winner without naming it. |
| 68 94.2% | differentiation h2 · 2× p · 39 w | Under the same heading, the attack on marketers is replaced by a concession: several listed products meet the same three standards. The brand is then said to stand out for the best package beyond them. | candorcontrast most-aware | After the facts, a fairness argument. It is kept for the close, where conceding ground to rivals can no longer cost the winner its first reading. | Twenty-three and twelve words. Fair, and flat: the concession is the most honest sentence on the page and the claim after it is an abstraction. | swap-mechanism Conceding that rivals pass the basic tests is already CS-P1's stance (its origin criterion is passed by all five). What we add is the name: The Cell Shield, astaxanthin spanning the whole cell membrane (m2, r5), third-party lab tested every batch (c3). CS-P1 never joins name and idea in one line. m2r5c3 |
| 69 95.7% | differentiation p · 16 w | One sentence names the three things said to set the winner apart: outside-lab testing, a free-from label and a genuine refund promise. | reason-whyrisk-reversal most-aware | It comes immediately before the link: the reader about to click is given three separators in place of the base page's reason for the price. | Sixteen words. Three of the four rival cards credit outside testing and the runner-up has the same refund window, so the separators barely separate. Price is missing, though price was the stated reason for second place. | swap-proof Ours separate for real, by our own reading of each rival's page: no rival posts a batch report, and ours is third-party lab tested every batch (c1, c3). CS-P1 says so in each rival card; its final block could say it once more. c1c3 |
| 70 96.3% | cta p · 5 w | The second link out repeats the first word for word: a soft invitation to read more about the winner. | commitmentease most-aware | It follows the argument about what sets the brand apart, about sixty percent of the page after the first link. The long gap is the price of the review pose: no link sits inside or between the rival cards. | Identical wording builds no escalation; the harder ask is held for the last line. | keep-structure CS-P1 spaces its CTA blocks more evenly (after the winner, mid-page, at the end) and has a sticky bar, so our reader is never sixty percent of a page from a button. Keep ours. |
| 71 96.8% | close h2 · p · 25 w | The final heading, then two sentences: meeting the standards only qualifies a product; testing, openness and the refund promise are what won first place. | reason-whyloop-closed most-aware | The close returns to the rule stated above the cards, so the page ends where its method began. Coming after the second link, it serves the reader who is still undecided. | Twenty-two words. The first sentence has a turn of phrase; the second is a list. The loss line and the four fragments of the base page are gone, and with them the close's rhythm and its only stake. | keep-structure CS-P1's final paragraph names its three points in one sentence and ends on the next labs. Ending on the method is calmer than ending on loss; for our reader the base page's fragments read better aloud. Rests on b7, b9, c3. b7b9c3 |
| 72 98.1% | cta p · 7 w | The final link changes the ask: try the winner, with the ninety-day risk-free window written into the link itself. | risk-reversalcommitment most-aware | Only the last link asks for a trial; the two before asked for a look. The escalation is saved for the reader who has read everything and needs the risk removed, not more information. | Seven words. The verb of trying plus the window makes the guarantee the call to action. It is the strongest of the three links. | swap-offer CS-P1's buttons already follow this pattern with the noun in them (try The Cell Shield, risk-free). The 30-Day Money-Back Guarantee is named in the line under the button. |
| 73 99.6% | page-furniture fine · 8 w | A copyright line names a publication, Daily Health Report, as the rights holder for 2026. | borrowed-authority most-aware | The publication is named only here, in the last row, in small type. The top of the page shows a byline with no masthead, so the publisher's name is present for form and unseen in practice. | Eight words. The page lives on the seller's own store domain while the footer credits a news-style publisher: the two do not agree. Treat the publication as a label, not an outlet. | page-furniture CS-P1 has a full publication identity (The Healthy Aging Review) in masthead and footer, on its own prelander site. Already there, and consistent from top to bottom. |